Halozyme Therapeutics, Inc. announced that the Company is reiterating its financial guidance for 2024, which was initially provided on January 17, 2024. For the full year 2024, the Company expects: Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED®. Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.48 USD | -0.13% | -0.74% | +23.05% |
May. 22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.05% | 5.79B | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.67% | 21.97B | |
-4.64% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024